Business Context and Reporting Period
Company: Geron Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2004
Business Overview: Geron is a biopharmaceutical company focused on developing therapeutic and diagnostic products for cancer based on telomerase technology and cell-based therapeutics using human embryonic stem cell (hESC) technology. The company has no approved products on the market and relies on research funding, license fees, and royalties.
Key Financial Metrics
| Metric | Q1 2004 | Q1 2003 |
|---|---|---|
| Total Revenues | $248,000 | $262,000 |
| Net Loss | $(51,683,000) | $(7,932,000) |
| Loss Per Share (Basic & Diluted) | $(1.28) | $(0.32) |
| Cash and Cash Equivalents | $6,529,000 | $7,089,000 |
| Marketable Securities | $92,673,000 | $96,427,000 |
| Total Current Assets | $109,366,000 | $111,808,000 |
| Total Current Liabilities | $7,040,000 | $9,825,000 |
| Accumulated Deficit | $(307,349,000) | $(255,666,000) |
Operating Expenses: Total operating expenses were $52.26 million, driven primarily by a $45.15 million charge for acquired in-process research technology. Research and development expenses were $5.72 million. General and administrative expenses were $1.39 million.
Cash Flow: Net cash used in operating activities was $9.99 million. Net cash provided by investing activities was $3.04 million, and net cash provided by financing activities was $0.65 million.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased significantly from $7.9 million in Q1 2003 to $51.7 million in Q1 2004. This was primarily due to a one-time non-cash expense of $45.2 million for the acquisition of in-process research technology from Merix Bioscience, Inc.
- Revenue Decline: Total revenues decreased slightly to $248,000 from $262,000. Revenues from collaborative agreements dropped to zero from $36,000, while license fees and royalties increased slightly to $248,000 from $226,000.
- R&D Expenses: Research and development expenses decreased to $5.7 million from $6.9 million, attributed to reduced personnel costs and lower raw material costs for clinical trial drugs.
- Liquidity: Cash and cash equivalents decreased by approximately $6.3 million during the quarter, while total liquid assets (cash plus marketable securities) remained substantial at roughly $99.2 million.
Guidance, Outlook, and Risks
Outlook and Capital Resources: Management estimates that existing capital resources, interest income, and equipment financing will fund operations through June 30, 2006. The company expects to incur additional operating losses as development efforts continue and anticipates a need for substantial additional capital in the future.
Key Developments:
- Merix Acquisition: Acquired co-exclusive rights to Merix Bioscience patents for therapeutic cancer vaccines in exchange for 5 million shares of common stock. The technology is being used in a Phase I/II clinical trial at Duke University.
- Stock Issuances: Issued shares to Transgenomic, Inc. for supply agreements and to the David D. Bohannon Organization for lease payments and termination.
Risks and Contingencies:
- Legal Proceedings: On April 28, 2004, Kirin Brewery Co., Ltd. filed a lawsuit alleging interference with contract and prospective business advantage regarding the Merix acquisition.
- Regulatory and Development Risk: The company has no products on the market. Success depends on preclinical and clinical trials, regulatory approvals, and manufacturing capabilities, all of which are uncertain.
- Intellectual Property: The company faces risks regarding patent interferences and the ability to enforce proprietary rights, particularly in Europe regarding human embryonic stem cells.
- Competition: Intense competition exists from larger pharmaceutical companies with greater resources.
Investor Verification Checklist
- Merix Transaction Impact: Verify the status of the $45.2 million non-cash charge and the progress of the Phase I/II clinical trial utilizing the acquired technology.
- Kirin Lawsuit: Monitor the status of the lawsuit filed by Kirin Brewery Co., Ltd. regarding the Merix acquisition and potential impacts on the cancer vaccine program.
- Cash Burn Rate: Confirm the runway of approximately $99 million in liquid assets against the projected operating expenses and the timeline for needing additional capital beyond mid-2006.
- Revenue Sustainability: Assess the reliance on license fees and royalties versus the lack of product sales revenue, noting the expectation of no therapeutic product revenue for several years.
- Stock Dilution: Review the impact of recent stock issuances (5 million shares to Merix, plus shares for leases and supplies) on shareholder equity and future dilution risks.